LP
Distinguished in Primary Lymphoma of the Brain

Dr. Leslie L. Popplewell

Duarte
Duarte, CA
Distinguished
 in Primary Lymphoma of the Brain
Specialties:Hematology | Hematology Oncology
Experience:31 Years
Age:57
Clinical Trials:Currently Recruiting for 4 Trials
Accepts:Medicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

    View 22 More Conditions +
    Check Dr. Leslie L. Popplewell's experience treating your condition:
    About Dr. Leslie L. Popplewell

    Leslie Popplewell is a Hematologist and a Hematologist Oncology doctor in Duarte, California. Dr. Popplewell has been practicing medicine for over 31 years and is rated as a Distinguished doctor by MediFind in the treatment of Primary Lymphoma of the Brain. She is also highly rated in 31 other conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

    Her clinical research consists of co-authoring 72 peer reviewed articles and participating in 21 clinical trials in the past 15 years.

    Insurance

    MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Leslie L. Popplewell it is best to call her office and ask if your insurance is accepted.

    Accepts Medicare
    Call to see if your plan is accepted.
    Locations
    1500 E Duarte Rd, Duarte, CA 91010
    Other Locations
    301 W. Huntington Drive, Suite 400, Arcadia, CA 91007
    Background & Education
    Graduate Institution
    University Of Louisville School Of Medicine, 1992
    Specialties
    Hematology
    Hematology Oncology
    Licenses
    Internal Medicine in AZ
    Hospital Affiliations
    City Of Hope Helford Clinical Research Hospital
    Languages Spoken
    English
    Gender
    Female
    Clinical Research

    Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

    18 Clinical Trials
    An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
    Enrollment Status: Recruiting
    Publish Date: April 03, 2023
    Intervention Type: Drug
    Study Phase: Phase 2
    A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
    Enrollment Status: Recruiting
    Publish Date: January 05, 2023
    Intervention Type: Drug
    Study Drugs: PalbociclibIbrutinib
    Study Phase: Phase 2
    A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
    Enrollment Status: Recruiting
    Publish Date: January 04, 2023
    Intervention Type: Biological, Procedure, Other
    Study Drug: Rituximab
    Study Phase: Phase 3
    Pilot/Feasibility Study of CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Following Autologous Hematopoietic Stem Cell Transplantation for Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma (B-NHL)
    Enrollment Status: Recruiting
    Publish Date: December 12, 2022
    Intervention Type: Procedure, Biological
    Study Phase: Phase 1
    A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
    Enrollment Status: Active, not recruiting
    Publish Date: April 04, 2023
    Intervention Type: Drug, Biological
    Study Drugs: IxazomibLenalidomideDexamethasone
    Study Phase: Phase 2
    Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: March 31, 2023
    Intervention Type: Biological, Other
    Study Drugs: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cellsAutologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    Study Phase: Phase 1
    A Phase I/II Study of VELCADE in Combination With Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: March 21, 2023
    Intervention Type: Drug, Biological, Other
    Study Drugs: RituximabBortezomibGemcitabine Hydrochloride
    Study Phase: Phase 1/Phase 2
    A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
    Enrollment Status: Active, not recruiting
    Publish Date: February 13, 2023
    Intervention Type: Drug, Other, Procedure
    Study Drugs: CarmustineCyclophosphamideCytarabineEtoposideIbrutinibMelphalan
    Study Phase: Phase 3
    Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: February 02, 2023
    Intervention Type: Biological, Procedure, Other, Drug
    Study Drugs: filgrastimrituximabgenetically engineered lymphocyte therapyplerixafor
    Study Phase: Phase 1/Phase 2
    Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: January 05, 2023
    Intervention Type: Biological, Other, Procedure
    Study Drug: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
    Study Phase: Phase 1
    A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: December 09, 2022
    Intervention Type: Drug
    Study Drugs: MagrolimabRituximabGemcitabineOxaliplatin
    Study Phase: Phase 1/Phase 2
    A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: November 03, 2022
    Intervention Type: Biological
    Study Drug: Tisagenlecleucel
    Study Phase: Phase 2
    Phase I Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: October 19, 2022
    Intervention Type: Drug
    Study Drugs: VenetoclaxLenalidomideRituximab
    Study Phase: Phase 1
    Managed Access Program (MAP) Cohort Treatment Plan CCTL019B2003I to Provide Access for Patients With Out of Specification Leukapheresis Product and/or Out of Specification Manufactured Tisagenlecleucel (CTL019; Kymriah®)
    Enrollment Status: Available
    Publish Date: September 06, 2022
    Intervention Type: Biological
    A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma
    Enrollment Status: Completed
    Publish Date: March 06, 2018
    Intervention Type: Other, Drug
    Study Phase: Phase 2
    A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Leukemia (AL) or in Newly Diagnosed Patients Over the Age of 60
    Enrollment Status: Terminated
    Publish Date: September 09, 2014
    Intervention Type: Genetic, Drug, Other
    Study Phase: Phase 2
    A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
    Enrollment Status: Completed
    Publish Date: February 15, 2013
    Intervention Type: Other, Drug
    Study Phase: Phase 1
    A Phase I Study of the Combination of Lenalidomide With the Histone Deacetylase Inhibitor, Vorinostat in Hodgkin and Non Hodgkin's Lymphoma
    Enrollment Status: Terminated
    Publish Date: December 09, 2010
    Intervention Type: Drug, Other
    Study Phase: Phase 1
    View 14 Less Clinical Trials -
    72 Total Publications
    Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Journal: The Lancet. Haematology
    Published: June 15, 2022
    Save this doctor for later
    Sign Up
    Looking for the best doctor for you?
    Start Here
    Is this your doctor?
    Find a second opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn more
    Similar Doctors
    MM
    Dr. Matthew G. Mei
    Hematology | Hematology Oncology
    Distinguished
    Highly rated in
    25
    conditions
    Hematology
    Hematology Oncology

    City of Hope

    Duarte

    1500 E Duarte Rd, 
    Duarte, CA 

    Matthew Mei is a Hematologist and a Hematologist Oncology doctor in Duarte, California. Dr. Mei has been practicing medicine for over 16 years and is rated as an Elite doctor by MediFind in the treatment of Primary Lymphoma of the Brain. He is also highly rated in 25 other conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

    AH
    Alex F. Herrera
    Dr. Alex F. Herrera
    Hematology | Hematology Oncology
    Distinguished
    Highly rated in
    22
    conditions
    Hematology
    Hematology Oncology

    City of Hope

    City Of Hope - Duarte Main Campus

    1500 E Duarte Rd, 
    Duarte, CA 
     0.1 mi

    Alex Herrera is a Hematologist and a Hematologist Oncology doctor in Duarte, CA. Dr. Herrera has been practicing medicine for over 14 years and is rated as an Elite doctor by MediFind in the treatment of Primary Lymphoma of the Brain. He is also highly rated in 22 other conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Herrera is currently accepting new patients.

    AM
    Dr. Ann F. Mohrbacher
    Hematology Oncology | Hematology | Oncology
    Distinguished
    Highly rated in
    30
    conditions
    Hematology Oncology
    Hematology
    Oncology

    Keck Medicine of USC

    USC Norris Comprehensive Cancer Center & Hospital

    1441 Eastlake Ave, 
    Los Angeles, CA 
     14.2 mi

    Ann Mohrbacher is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Mohrbacher has been practicing medicine for over 36 years and is rated as a Distinguished doctor by MediFind in the treatment of Primary Lymphoma of the Brain. She is also highly rated in 30 other conditions, according to our data. Her top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Mohrbacher is currently accepting new patients.